Caplin Point Laboratories Ltd. is a fast-growing, fully integrated pharmaceutical company thriving in Francophone Africa and Latin America. It manufactures a wide range of creams, ointments, and other external application preparations, along with regular segments of pharmaceutical formulations. The company was incorporated in 1990, with its headquarters in Chennai. Its total income for the June 2022 quarter was Rs 360.27 crore, up 2.71% from Rs 350.75 crore in the March 2022 quarter. On 30 August 2022, the company’s market capitalisation stood at Rs 5,903 crore.
The company’s Bombay Stock Exchange listing code is 524742, and the National Stock Exchange listing code is CAPLIPOINT.
Caplin Point Laboratories Ltd. is one of the leading suppliers of pharmaceuticals in the markets of Latin America, Southern and Francophone Africa, and the Caribbean, with more than 4,000 product licenses worldwide. The company prospers on a unique business model of owning distribution networks, predominantly targeting the bottom of the pyramid.
On 30 June 2022, the company’s shareholding pattern reflected a 1.11% domestic institutional investor stake, a 2.03% foreign institutional investor stake, a 27.97% public stake, and a 68.88% promoter stake. In the June 2022 quarter, promoter holdings decreased from 68.89% to 68.88%, mutual fund holdings decreased from 1.19% to 1.06%, and FII holdings decreased from 2.07% to 2.03%.
The company’s board of directors comprises Mr C CPaarthipan, Dr Sridhar Ganesan, Mr D Sathyanarayanan, Mr V Thirumalai, Dr KC John, Dr (Mrs) C K Gariyali, and Mr R Viswanathan. The auditors of the company are CNGSN & Associates LLP. On 30 June 2022, the company had a total of 7.58 crore shares outstanding.
On 30 August 2022, Caplin Point Laboratories Ltd.’s share price closed at Rs 776.90 on BSE and at Rs 778.80 on NSE. The 52-week high for Caplin Point Laboratories Ltd.’s share price was Rs 1,008.40, and the 52-week low for the company’s share price was Rs 626.
As of July 2022, the company’s top mutual fund holdings included Taurus Discovery (Midcap) Fund, Taurus Ethical Fund, and Quant Small Cap Fund, with a 3.36% stake, 3.08% stake, and 2.43% stake, respectively.
Caplin Point Laboratories Ltd.’s peers include Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., Cipla Ltd., and Dr Reddys Laboratories Ltd.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose
Invest
FAQ’s on Caplin Point Laboratories Ltd Shares
